These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 33539944)

  • 1. A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis.
    Brufsky A; Kim SB; Zvirbule Ž; Eniu A; Mebis J; Sohn JH; Wongchenko M; Chohan S; Amin R; Yan Y; McNally V; Miles D; Loi S
    Ann Oncol; 2021 May; 32(5):652-660. PubMed ID: 33539944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    Schmid P; Adams S; Rugo HS; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Hegg R; Im SA; Shaw Wright G; Henschel V; Molinero L; Chui SY; Funke R; Husain A; Winer EP; Loi S; Emens LA;
    N Engl J Med; 2018 Nov; 379(22):2108-2121. PubMed ID: 30345906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
    Miles D; Gligorov J; André F; Cameron D; Schneeweiss A; Barrios C; Xu B; Wardley A; Kaen D; Andrade L; Semiglazov V; Reinisch M; Patel S; Patre M; Morales L; Patel SL; Kaul M; Barata T; O'Shaughnessy J;
    Ann Oncol; 2021 Aug; 32(8):994-1004. PubMed ID: 34219000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cobimetinib plus atezolizumab in BRAF
    Gogas H; Dréno B; Larkin J; Demidov L; Stroyakovskiy D; Eroglu Z; Francesco Ferrucci P; Pigozzo J; Rutkowski P; Mackiewicz J; Rooney I; Voulgari A; Troutman S; Pitcher B; Guo Y; Yan Y; Castro M; Mulla S; Flaherty K; Arance A
    Ann Oncol; 2021 Mar; 32(3):384-394. PubMed ID: 33309774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
    Adams S; Diamond JR; Hamilton E; Pohlmann PR; Tolaney SM; Chang CW; Zhang W; Iizuka K; Foster PG; Molinero L; Funke R; Powderly J
    JAMA Oncol; 2019 Mar; 5(3):334-342. PubMed ID: 30347025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
    Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
    Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
    Kang C; Syed YY
    Drugs; 2020 Apr; 80(6):601-607. PubMed ID: 32248356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
    Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F;
    Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130).
    Iwata H; Inoue K; Kaneko K; Ito Y; Tsugawa K; Hasegawa A; Nakagawa S; Kuratomi H; Tamura K
    Jpn J Clin Oncol; 2019 Dec; 49(12):1083-1091. PubMed ID: 31612909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
    Li CH; Karantza V; Aktan G; Lala M
    Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
    Adams S; Diéras V; Barrios CH; Winer EP; Schneeweiss A; Iwata H; Loi S; Patel S; Henschel V; Chui SY; Rugo HS; Emens LA; Schmid P
    Ann Oncol; 2020 May; 31(5):582-589. PubMed ID: 32178964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
    Emens LA; Adams S; Barrios CH; Diéras V; Iwata H; Loi S; Rugo HS; Schneeweiss A; Winer EP; Patel S; Henschel V; Swat A; Kaul M; Molinero L; Patel S; Chui SY; Schmid P
    Ann Oncol; 2021 Aug; 32(8):983-993. PubMed ID: 34272041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer.
    Dent R; André F; Gonçalves A; Martin M; Schmid P; Schütz F; Kümmel S; Swain SM; Bilici A; Loirat D; Villalobos Valencia R; Im SA; Park YH; De Laurentis M; Colleoni M; Guarneri V; Bianchini G; Li H; Kirchmayer Machackova Z; Mouta J; Deurloo R; Gan X; Fan M; Mani A; Swat A; Cortés J
    Ann Oncol; 2024 Jul; 35(7):630-642. PubMed ID: 38755096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
    Dummer R; Queirolo P; Abajo Guijarro AM; Hu Y; Wang D; de Azevedo SJ; Robert C; Ascierto PA; Chiarion-Sileni V; Pronzato P; Spagnolo F; Mujika Eizmendi K; Liszkay G; de la Cruz Merino L; Tawbi H
    Lancet Oncol; 2022 Sep; 23(9):1145-1155. PubMed ID: 35940183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF
    Gutzmer R; Stroyakovskiy D; Gogas H; Robert C; Lewis K; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Manikhas GM; Yan Y; Huang KC; Uyei A; McNally V; McArthur GA; Ascierto PA
    Lancet; 2020 Jun; 395(10240):1835-1844. PubMed ID: 32534646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J;
    Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.
    Hellmann MD; Kim TW; Lee CB; Goh BC; Miller WH; Oh DY; Jamal R; Chee CE; Chow LQM; Gainor JF; Desai J; Solomon BJ; Das Thakur M; Pitcher B; Foster P; Hernandez G; Wongchenko MJ; Cha E; Bang YJ; Siu LL; Bendell J
    Ann Oncol; 2019 Jul; 30(7):1134-1142. PubMed ID: 30918950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031).
    Saji S; Ohsumi S; Ito M; Hayashi N; Kobayashi K; Masuda N; Niikura N; Yamashita T; Kiyama K; Hasegawa A; Nakagawa S; Hattori M
    Jpn J Clin Oncol; 2022 Oct; 52(10):1124-1133. PubMed ID: 35750038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
    Emens LA; Cruz C; Eder JP; Braiteh F; Chung C; Tolaney SM; Kuter I; Nanda R; Cassier PA; Delord JP; Gordon MS; ElGabry E; Chang CW; Sarkar I; Grossman W; O'Hear C; Fassò M; Molinero L; Schmid P
    JAMA Oncol; 2019 Jan; 5(1):74-82. PubMed ID: 30242306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.